Compare Clorox Co (CLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs State Street SPDR S&P Biotech ETF — how do they compare? Clorox Co trades at $106.1 (market cap $13.09B), while State Street SPDR S&P Biotech ETF trades at $159.29. The key difference: Clorox Co pays a 4.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Clorox Co nearer its low. Which is the better fit depends on your goals.
| CLX | XBI | |
|---|---|---|
Market Cap | $13.09B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $127.16 | $164.28 |
52-Week Low | $86.12 | $86.92 |
Enterprise Value | $18.47B | — |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $106.30, down 1.3% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $1.66, though Q4 2025 missed. The company reported FY2025 revenue of $7.10B and net income of $810M, with improving margins. A dividend increase to $1.25 per share was announced, payable in August 2026.
Outlook is mixed: strong profitability and dividend support value, but high P/E of 22.51 and modest revenue growth pose valuation concerns. Analyst consensus is cautious with a $97.50 price target below current levels. Risks include inflation pressures and competitive threats from private labels, limiting near-term upside potential.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
